MicroRNA‐200a suppresses prostate cancer progression through BRD4/AR signaling pathway
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Medicine"
DOI: 10.1002/cam4.2029
Abstract: Prostate cancer is still considered a significant health care challenge worldwide due in part to the distinct transformation of androgen‐dependent prostate cancer (ADPC) into treatment‐refractory castration‐resistant prostate cancer (CRPC). Consequently, there is an urgent need… read more here.
Keywords: prostate cancer; cancer; mir 200a; 200a suppresses ... See more keywords
PRKAR2B promotes prostate cancer metastasis by activating Wnt/β‐catenin and inducing epithelial‐mesenchymal transition
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27030
Abstract: Castration‐resistant prostate cancers (CRPC) that occur after the failure of androgen‐blocking therapies cause most of the deaths in prostate cancer (PCa) patients. In a previous study we identified that PRKAR2B expression is upregulated in CRPC… read more here.
Keywords: prostate cancer; metastasis; prkar2b; cancer ... See more keywords
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers
Sign Up to like & getrecommendations! Published in 2022 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06714-8
Abstract: The effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial… read more here.
Keywords: bone; bone metastases; longer term; bone modifying ... See more keywords
Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.08.014
Abstract: Early studies suggested that using ADT with the recently developed anti-androgen Enzalutamide (Enz, also named as MDV3100 could extent castration resistant prostate cancer (CRPC) patients' survival an extra 4.8 months. Yet the therapy in most… read more here.
Keywords: androgen; ephb6 suppressor; ephb6; cancer ... See more keywords
PCN168 Lutetium (177LU) Oxodotreotide Versus Standard of Care in Adult Patients with Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): A Cost-Consequences Analysis from an Italian Hospital Perspective
Sign Up to like & getrecommendations! Published in 2020 at "Value in Health"
DOI: 10.1016/j.jval.2020.08.305
Abstract: more, one-to-one web-meeting among 35 clinical experts specialized in urological diseases was conducted to collect relevant epidemiological, survival and costs information based on the pre-designed questionnaire. CRPC economic burden model was developed using Microsoft Excel… read more here.
Keywords: survival; analysis; cny; cost ... See more keywords
Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "Oncogene"
DOI: 10.1038/onc.2017.385
Abstract: Androgen receptor (AR) is a transcriptional activator that, in prostate cells, stimulates gene expression required for various cellular functions, including metabolisms and proliferation. AR signaling is also essential for the development of hormone-dependent prostate cancer… read more here.
Keywords: prostate; prostate cancer; castration resistant; cancer ... See more keywords
Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2017.64
Abstract: Castration-resistant prostate cancer (CRPC) remains a major clinical challenge because of the lack of effective targeted therapy for its treatment. The mechanism underlying how CRPC gains resistance toward hormone depletion and other forms of chemotherapy… read more here.
Keywords: prostate; skp2; progression; cancer ... See more keywords
Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-01887-2
Abstract: Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-associated coregulators and chromatin proteins hold a great potential for novel therapy targets. Here, we employed a powerful chromatin-directed proteomics approach termed ChIP-SICAP to… read more here.
Keywords: crpc cells; androgen; prostate cancer; crpc ... See more keywords
Effect of Dietary Omega-3 Fatty Acids on Castrate Resistant Prostate Cancer and Tumor Associated Macrophages
Sign Up to like & getrecommendations! Published in 2019 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-019-0168-8
Abstract: Background M2-like macrophages are associated with the pathogenesis of castrate-resistant prostate cancer (CRPC). We sought to determine if dietary omega-3 fatty acids (ω-3 FAs) delay the development and progression of CRPC and inhibit tumor-associated M2-like… read more here.
Keywords: prostate cancer; omega fatty; dietary omega; castrate resistant ... See more keywords
Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/srep40957
Abstract: Androgen receptor variants (AR-Vs) provide a mechanism of therapy evasion in castrate-resistant prostate cancer (CRPC), yet mechanisms of regulation remain largely unknown. Here we investigate the role of Aurora A kinase on AR-Vs in models… read more here.
Keywords: crpc; resistant prostate; castrate resistant; prostate cancer ... See more keywords
Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.
Sign Up to like & getrecommendations! Published in 2023 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2218522120
Abstract: Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic hormonal therapy, a stage known as castration-resistant… read more here.
Keywords: drug discovery; resistant prostate; castration resistant; crpc ... See more keywords